Substance P (SP) is one of the most abundant peptides in the central nervous system and
has been implicated in a variety of physiological and pathophysiological processes …

The G protein–coupled receptor (GPCR), neurokinin‐1 receptor (NK1R), and its preferred
ligand, substance P (SP), are reviewed in relationship to the immune system and selected …

Repetitive transcranial magnetic stimulation (rTMS) is increasingly used as a therapeutic
tool in various neurological and psychiatric disorders, and we recently found that it has a …

Cholecystokinin (CCK) involvement in depression-like disorders is poorly documented.
Here, we investigated whether CCKergic neurotransmission is relevant to depressive-like …

Research on Substance P (SP) has, until recently, focused on its role in pain and
inflammation. However, a report that NK1 receptor antagonists have utility in the treatment of …

The involvement of cholecystokinin (CCK) in the mechanisms of stress and/or anxiety was
assessed by in vivo microdialysis in rats subjected to a social stress paradigm. During the …

Electroconvulsive therapy is used in the treatment of affective disorders and schizophrenia
and experimental electroconvulsive shock may serve as an animal model for this treatment …

The newly identified neuropeptide nociceptin/orphanin FQ (NOC) was measured in different
rat brain areas related to the descending anti-nociceptive pathways and compared to two …

Cholecystokinin (CCK) has well-documented anxiogenic effects in animals and normal
people, and panicogenic effects in patients with panic disorder, but little is known about its …

Cholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in
the highest levels in cortical and limbic structures and also in the basal ganglia. Two …